Recent investigations have centered on the intersection of glucagon-like peptide-1|GIP|GCGR agonist therapies and dopaminergic signaling. While GCGR agonists are widely employed for treating type 2 T2DM, their emerging consequences on reinforcement circuits, specifically governed by dopaminergic networks, are attracting significant attention. This